* ¼Òȱ⳻°ú Àü¹®ÀÇ ¼±»ý´Ô ä¿ë
¾÷¹«
1) GI therapeutic area drugs °ü·Ã ¾÷¹«
2) Medical affairs ¾÷¹«
3) KOL management
4) New drug launching project ´ã´ç
5) Medical Director(VP)¿¡°Ô report
°³²¿¡ À§Ä¡ÇÑ ´Ù±¹Àû Á¦¾à ±â¾÷ÀÇ MDä¿ë ÀÔ´Ï´Ù.
ÀÚ°Ý
1) ¼Òȱ⳻Àü¹®ÀÇ, ³»°úÀü¹®ÀÇ
2) ¿µ¾î ÀÎÅÍºä °¡´ÉÇÑ ºÐ
3) Á¦¾à ±â¾÷ °æ·ÂÀÚ´Â ¿ì´ë
* ¹ÙÀÌ·¯½ºÁúȯ Ä¡·áÁ¦´ã´ç medical advisor ä¿ë
1. ¹ÙÀÌ·¯½º Áúȯ Ä¡·á°ü·Ã ¼±»ý´Ôµé°ú Á¦Ç°ÀÇ discussion
2. ¹ÙÀÌ·¯½º Áúȯ Ä¡·á °ü·Ã ¼±»ý´Ôµé ½ÉÆ÷Áö¾ö ÁøÇà
3. ½ÉÆ÷Áö¾ö ¼¼¼Ç ¹ßÇ¥ ¹× ¹ßÇ¥ÀÚ ¼±»ý´Ô ¼·¿Ü
4. º»»ç Á¦Ç° Á¤º¸ review
5. Country Medical Head¿¡°Ô º¸°í
6. °ü·Ã ÇÐȸ °ü¸®
l ³»°ú, °¡Á¤ÀÇÇаú ¼±»ý´Ô
l ¼Ò¾Æ°ú ¼±»ý´Ô
l ¿µ¾î Ä¿¹Â´ÏÄÉÀ̼ÇÀÌ °¡´ÉÇϽŠºÐ
* Rare Disease ÀǾàÇ° ´ã´ç ¼±»ý´ÔÀ» ã½À´Ï´Ù
l Rare DiseaseÀǾàÇ° ´ã´ç medical affairs ¾÷¹«
l ¼Ò¾Æ°ú, ³»°ú KOL ¼±»ý´Ôµé°ú Ä¡·áÀǾàÇ° °³¹ß discussion
l ½Å¾à ·ÐĪ °ü·Ã ½ÉÆ÷Áö¿ò ÁÖÃÖ
l ½ÉÆ÷Áö¿ò ¹ßÇ¥ ¹× ¹ßÇ¥ ±³¼ö´Ô ¼·¿Ü
l Commercial ºÎ¼¿ÍÀÇ Çù·Â
l Medical director¿¡°Ô º¸°í
l ÇØ¿Ü ÃâÀå
l Àü¹®ÀÇ ¼±»ý´Ô
l ¿µ¾î·Î ÀÎÅÍºä °¡´ÉÇÑ ¼±»ý´Ô
l ¼Ò¾Æ°ú, ³»°ú, °¡Á¤ÀÇÇÐ, Áø´Ü°Ë»ç ¼±»ý´Ô ¿ì´ë
* oncology ÀǾàÇ° medical advisor ä¿ëä¿ë
l Oncology ÀǾàÇ° °ü·Ã medical affairs ¾÷¹«
l Oncology °ü·Ã Á¾¾ç³»°ú ¼±»ý´Ôµé°úÀÇ ¿¬±¸ ÇùÀÇ
l KOL Management
l º»»ç ¿¬±¸°³¹ß ÁßÀÎ ½Å¾à°ü·Ã ¾÷¹«
l ÇÐȸ ¹× ÇØ¿Ü ½ÉÆ÷Áö¾ö Âü°¡
l Á¦¾à±â¾÷¿¡ °ü½É ÀÖ´Â Àü¹®ÀÇ ¼±»ý´Ô
l ³»°ú, °¡Á¤ÀÇÇÐÀ» Æ÷ÇÔÇÑ Àü°øºÐ¾ßÀÇ ¼±»ý´Ô
l ÇØ¿Ü ÇÐȸ Âü¼® ¹× ¿µ¾î ÀÎÅÍºä °¡´ÉÇϽŠºÐ
* ±¹³» ¹ÙÀÌ¿À´ë±â¾÷¿¡¼ Áø´Ü°Ë»çÀÇÇÐ Àü¹®ÀÇ ¼±»ý´ÔÀ» ä¿ë ÇÕ´Ï´Ù.
l Áø´Ü °Ë»ç ¿¬±¸ °ü·Ã KOL°ú ¹ÌÆÃ
l Áø´Ü °Ë»ç ¿¬±¸°ü·Ã ÇØ¿Ü Business Development
l À¯ÀüÀÚ ¿¬±¸ °ü·Ã project ¼öÇà
l Áø´Ü °ü·Ã ´ë°ü ¾÷¹« support
l ÇØ¿Ü ÇÐȸ Âü¼® ¹× ÇØ¿Ü ÆÄÆ®³Ê»ç ¹ÌÆà Âü¼®
l ȸ»ç ¿¬±¸°³¹ß ±×·ì°ú ¼öÇà project discussion
l Áø´Ü °Ë»ç Àü¹®ÀÇ ¼±»ý´Ô
l ¿µ¾î·Î ÇØ¿Ü ÇÐȸ Âü¼®ÀÌ °¡´ÉÇÑ ºÐ
ä¿ëÀº ºÎÀå ~ ÀÌ»çÁ÷±ÞÀ¸·Î ÁøÇà µË´Ï´Ù.
Á÷¾÷Á¤º¸Á¦°ø»ç¾÷½Å°í¹øÈ£ J150002023003